Gevokizumab: Phase III started

Xoma began the double-blind, U.S. Phase III EYEGUARD-US trial to evaluate 60 mg subcutaneous gevokizumab once monthly in up to 28 patients with Behcet's uveitis. All patients will receive gevokizumab until day 28, when patients will be randomized to receive gevokizumab or placebo. Gevokizumab is in the Phase III EYEGUARD program to treat non-infectious uveitis and Behcet's uveitis. ...